TCTMD
Talking Points
A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe.06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
N'hésitez pas à visiter le site du podcast et à soutenir son créateur : soundcloud.com
Où écouter ?
Les podcasts dans l'appli Replaio Radio Bientôt disponibleLes podcasts arrivent très bientôt dans l'appli. Installe-la dès maintenant et découvre en avant-première une toute nouvelle façon de vivre les podcasts
Installe-la gratuitement
Android près de 10 M de téléchargements · note de 4,8
iOS bientôt
Épisodes
Episode 160: Shock Classification Gets an Update 02.11.2022 4:06
C. Michael Gibson and Timothy Henry discuss key updates to the SCAI SHOCK classifications.
Episode 159: MICHELLE: Rivaroxaban in COVID-19 19.10.2022 7:37
C. Michael Gibson and Renato Lopes discuss extended DOAC prophylaxis in medically ill, hospitalized patients with COVID-19.
Episode 158: The RIPCORD 2 Trial 05.10.2022 10:33
C. Michael Gibson and Nicholas Curzen discuss whether routine pressure-wire assessment influences the use of coronary angiography for diagnosing chest pain.
Episode 157: PARTNER 3: Two-Year Economic Outcomes 14.09.2022 4:33
C. Michael Gibson and David Cohen discuss cost implications of this TAVI versus SAVR randomized trial.
Episode 156: The IAMI Trial 07.09.2022 8:19
C. Michael Gibson and Ole Fröbert discuss the potential for influenza vaccination in post-MI patients.
Episode 155: Two DCBs Go Head to Head in De Novo CAD 25.08.2022 12:14
C. Michael Gibson and Wan Azman Wan Ahmad discuss a sirolimus-versus a paclitaxel-coated balloon in de novo coronary lesions.
Episode 154: The EMPEROR-Preserved Trial 10.08.2022 5:14
C. Michael Gibson and Stefan Anker discuss the effects of empagliflozin on CV death and HF hospitalizations in patients with HFpEF, with and without diabetes.
Episode 153: iFR-SWEDEHEART at 5 Years 03.08.2022 6:30
C. Michael Gibson and Matthias Götberg review 5-year findings after iFR- versus FFR-guided PCI.
Episode 152: PRONOUNCE: Prostate Cancer Drugs and CVD 20.07.2022 10:24
Renato Lopes and C. Michael Gibson discuss PRONOUNCE comparing the cardiovascular safety of degarelix vs. leuprolide in patients with advanced prostate cancer and CVD.
Episode 151: Stopping Amputation Post-revascularization: Novel Data in Mitigation of Thrombosis Risk 06.07.2022 9:01
Desai and Anahita Dua discuss highlights from a CME program on reducing thrombosis risks in patients with PAD post-revascularization. Claim credit: https://bit.ly/3QTpBt6. Supported by an educational grant from Janssen Scientific Affairs, LLC.
Episode 150: The TOMAHAWK Trial 06.07.2022 4:26
C. Michael Gibson and Steffen Desch discuss whether immediate angiography is warranted after out-of-hospital cardiac arrest.
Episode 149: The OPTIMUM Trial 22.06.2022 5:23
C. Michael Gibson and David Kandzari discuss PCI outcomes among patients at prohibitive risk for CABG.
Episode 148: The MASTER DAPT Trial 08.06.2022 9:00
C. Michael Gibson and Marco Valgimigli discuss dual antiplatelet therapy after coronary stenting in high-bleeding-risk patients.
Episode 147: The EROSION III Trial 01.06.2022 12:15
C. Michael Gibson, Haibo Jia, and Jingbo Hou discuss whether OCT guidance could cut stent use in STEMI without plaque rupture.
Episode 146: The LIFE Trial 18.05.2022 8:15
C. Michael Gibson and Douglas Mann discuss sacubitril/valsartan in patients with advanced HFrEF.
Episode 145: PRAGUE 17: LAA Closure vs DOACs 04.05.2022 11:46
C. Michael Gibson and Pavel Osmancik review 3-year results with LAA closure versus a DOAC for patients with atrial fibrillation.
Episode 144: MASTER DAPT: High-Risk Patients 20.04.2022 6:49
C. Michael Gibson and Pieter C. Smits review outcomes in high-bleeding-risk patients also at high risk for thrombotic events who were randomized to abbreviated DAPT.
Episode 143: The ADAPTABLE Study: Patient-Centered Aspirin 06.04.2022 13:45
C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt.
Episode 142: ISCHEMIA: Complete Revascularization and QoL 23.03.2022 6:38
C. Michael Gibson and Kreton Mavromatis discuss how completeness of revascularization impacts quality of life in stable ischemic heart disease patients.
Episode 141: The STRENGTH Study of Omega-3s 16.03.2022 12:56
C. Michael Gibson and Steven Nissen discuss the link between omega-3 fatty acid levels and MACE in patients with high cardiovascular risk.
Episode 140: The SWISS-APERO Trial 02.03.2022 4:03
C. Michael Gibson and Robert Galea discuss Amulet versus Watchman for LAA closure.
Episode 139: The 2021 ESC HF Guidelines 09.02.2022 11:15
C. Michael Gibson and Carolyn Lam discuss key updates to the European heart failure guidelines and how best to initiate medications to optimize outcomes.
Episode 138: The ATLANTIS Trial: DOACs in TAVI? 02.02.2022 14:54
C. Michael Gibson, Jean-Philippe Collet, and Gilles Montalescot and discuss apixiban after TAVI in the Atlantis trial.
Episode 137: Early Intrepid TMVR Results 12.01.2022 6:10
C. Michael Gibson and Firas Zahr discuss 30-day outcomes following transfemoral transseptal TMVR.
Episode 136: Two DCBs vs POBA in Coronary In-Stent Restenosis 05.01.2022 6:13
C. Michael Gibson and Bruno Scheller discuss 1-year outcomes of two parallel RCTs.
Podcasts similaires
Écoute le podcast Talking Points sur Replaio
La radio et les podcasts dans une seule appli - gratuite, sans inscription. Installe-la dès aujourd'hui et ne rate pas le lancement
Replaio n'est pas éditeur de podcasts ; les noms des émissions, les visuels et l'audio appartiennent à leurs auteurs et sont diffusés via des flux RSS publics
